Last updated: August 2, 2026
Nelarabine is a niche oncology drug used primarily for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The U.S. product, Arranon, was approved in 2005 under the FDA accelerated-approval pathway. Its commercial profile is shaped by orphan-disease demand, hospital purchasing, intravenous administration, limited treatment volume, and generic competition rather than by broad primary-care use. Public filings do not disclose standalone nelarabine revenue, so the financial trajectory must be assessed through product ownership, regulatory status, generic entry, pricing structure, and the performance of the relevant oncology portfolios.
What is nelarabine and how is it used?
Nelarabine is a prodrug of ara-G, a purine nucleoside analogue. It is converted to active metabolites that interfere with DNA synthesis in lymphoblasts. The drug is administered intravenously and is indicated for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma after treatment with at least two prior chemotherapy regimens.[1]
| Product |
Active ingredient |
Route |
Main indication |
FDA status |
| Arranon |
Nelarabine |
Intravenous infusion |
Relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma |
Approved |
| Atriance |
Nelarabine |
Intravenous infusion |
Similar T-cell malignancies in markets outside the U.S. |
Approved in selected jurisdictions |
| Generic nelarabine injection |
Nelarabine |
Intravenous infusion |
Same reference-product indications, subject to approved labeling |
Approved in the U.S. |
The product is used in a small population with serious disease and limited therapeutic alternatives. Its principal clinical constraints are neurotoxicity, myelosuppression, infection risk, and the need for inpatient or specialized outpatient administration.[1]
When did nelarabine lose exclusivity?
Nelarabine lost the commercial protection associated with its original U.S. approval years ago. The product’s relevant market protections include regulatory exclusivity, patent rights, and orphan-drug provisions, but none creates a current barrier equivalent to active new-molecule exclusivity.
FDA approval and regulatory exclusivity timeline
| Event |
Date |
Commercial significance |
| FDA approval of Arranon |
October 28, 2005 |
Initial U.S. marketing authorization |
| FDA orphan-drug designation and approval framework |
2005 |
Supported development in a rare cancer population |
| U.S. seven-year orphan exclusivity period |
Expired in 2012 |
No longer blocks approval of the same drug for the same indication |
| Expected end of five-year new chemical entity exclusivity |
2010 |
No longer relevant |
| Generic competition |
Entered after loss of primary exclusivity |
Reduced branded exclusivity and pricing power |
The FDA accelerated-approval pathway allowed approval based on response data in relapsed or refractory disease, with postmarketing obligations related to clinical benefit confirmation.[2] The product’s current market position therefore depends on continued clinical use, institutional protocols, supply reliability, and contracting rather than on residual regulatory exclusivity.
What patents protect nelarabine and Arranon?
The original nelarabine patent estate is mature. The principal commercial protection was directed to the compound and its use in T-cell malignancies, but those rights have reached or passed their ordinary patent terms.
Publicly available FDA and patent databases do not indicate a current, commercially significant blocking patent estate comparable to the patent portfolios surrounding newer targeted oncology products. Patent risk is therefore lower than regulatory, manufacturing, and procurement risk.
Patent categories relevant to nelarabine
| Patent category |
Historical relevance |
Current risk |
| Active pharmaceutical ingredient |
Covered nelarabine and related compounds |
Low after expiration of foundational rights |
| Treatment methods |
Covered use in T-cell leukemia and lymphoma |
Limited, subject to claim scope and jurisdiction |
| Formulation patents |
Potentially covered injectable compositions or stability |
No widely reported late-life formulation barrier |
| Manufacturing patents |
Could cover synthesis, purification, or intermediates |
Possible process-level barriers, but unlikely to block approved generic entry |
| Pediatric or orphan protections |
Extended regulatory market protection in defined settings |
Expired or no longer commercially decisive |
A definitive patent opinion requires a current jurisdiction-by-jurisdiction search of the USPTO, WIPO, European Patent Office, and national registers. The commercial conclusion remains clear: nelarabine is a mature small-molecule product with no publicly prominent late-life patent barrier preventing generic competition.
What is the Orange Book status of Arranon?
Arranon was listed in the FDA Orange Book as the reference product for nelarabine injection. Orange Book relevance has declined as the original exclusivity period ended and abbreviated new drug applications became possible.
The principal regulatory issues are:
- Whether a generic applicant has an approved ANDA referencing Arranon.
- Whether the ANDA includes a Paragraph IV certification against any listed patent.
- Whether the reference product has an active listed patent that could support a 30-month stay.
- Whether the generic product has the same concentration, dosage form, route, and labeling conditions.
Because nelarabine is an injectable oncology product, FDA approval also depends on manufacturing controls, sterility assurance, container-closure compatibility, and supply-chain compliance. Generic approval does not guarantee rapid commercial uptake if hospitals retain incumbent contracts or if supply is intermittent.
Which companies are challenging Arranon and competing with nelarabine?
The competitive field includes generic injectable manufacturers rather than direct branded substitutes. Publicly disclosed information supports the existence of generic nelarabine competition, but company-level market-share data are not consistently reported.
Competitive groups
| Competitor type |
Examples |
Competitive effect |
| Generic injectable manufacturers |
FDA-approved ANDA holders |
Price competition and tender pressure |
| Branded originator |
Arranon |
Reference-product recognition and institutional familiarity |
| Alternative salvage regimens |
Multiagent chemotherapy, nelarabine-containing protocols, clinical trials |
Limits treatment volume |
| Cellular therapies |
CAR-T and transplant pathways in selected patients |
Potential substitution in eligible patients |
| Other T-cell malignancy therapies |
Targeted or immunotherapy products |
Compete for treatment sequencing rather than direct interchangeability |
Nelarabine has a narrow indication. Many competing therapies are not therapeutically interchangeable and are selected based on age, prior therapy, disease burden, transplant eligibility, molecular profile, and institutional practice.
How does generic entry affect nelarabine pricing?
Generic entry is the strongest current commercial pressure on nelarabine. The market has several characteristics that can moderate or delay price erosion:
- The product is purchased primarily by hospitals and specialty distributors.
- The annual treated population is small.
- Injectable oncology products require validated sterile manufacturing.
- A shortage or manufacturing interruption can temporarily support incumbent pricing.
- Hospitals may use dual sourcing rather than immediately switching the entire product volume.
At the same time, the absence of active new-molecule exclusivity and the availability of approved generic pathways limit long-term branded pricing power. Net prices are likely to vary substantially by account, wholesaler, group purchasing organization, and shortage conditions.
Are there Paragraph IV challenges to nelarabine patents?
There is no widely reported, commercially material Paragraph IV litigation campaign around a current Arranon patent estate. This differs from high-value small molecules with multiple late-expiring formulation, dosing, or combination patents.
A generic applicant could still file a Paragraph IV certification if an Orange Book-listed patent remained active. The financial value of such a challenge would be limited by the small market size and the absence of a large chronic-treatment revenue stream. Generic applicants may prefer Paragraph III certifications, patent statements, or approval after patent expiration where litigation economics are unfavorable.
What formulation patents protect nelarabine injection?
Nelarabine is supplied as a sterile intravenous solution, commonly at a concentration of 5 mg/mL in a 50 mL vial containing 250 mg. The formulation is relatively straightforward compared with long-acting injectables, liposomal products, depot formulations, or complex biologics.[1]
The primary formulation risks are technical rather than exclusivity-driven:
- Maintaining chemical stability during storage.
- Controlling degradation products.
- Ensuring sterility and particulate limits.
- Matching container-closure performance.
- Demonstrating bioequivalence or pharmaceutical equivalence for the injectable product.
No widely recognized extended-release, oral, liposomal, or device-based nelarabine formulation has created a separate high-value lifecycle franchise.
What is the FDA regulatory status of nelarabine?
Nelarabine remains an FDA-approved oncology drug. The FDA label includes boxed-warning language concerning serious neurologic adverse reactions, including somnolence, seizures, peripheral neuropathy, and other central or peripheral nervous-system effects.[1]
Regulatory profile
| Regulatory factor |
Assessment |
| FDA approval |
Maintained |
| Approval pathway |
Accelerated approval |
| Disease area |
Relapsed or refractory T-cell malignancies |
| Administration |
Intravenous |
| Pediatric use |
Included in labeling, with age-specific dosing |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA pathway applicable |
| Postmarketing obligations |
Relevant to accelerated approval history and safety monitoring |
Nelarabine is a conventional small molecule, not a biologic. Biosimilar competition is therefore irrelevant. The competitive pathway is generic substitution through ANDAs, not applications under the Public Health Service Act.
How strong is the nelarabine patent estate?
The patent estate is commercially weak relative to newer oncology drugs. Its strengths are historical compound protection and clinical familiarity. Its weaknesses are the age of the product, expiration of core exclusivity, lack of a differentiated delivery system, and generic substitutability.
| Patent-estate factor |
Commercial assessment |
| Foundational compound protection |
Mature or expired |
| Orphan exclusivity |
Expired |
| New chemical entity exclusivity |
Expired |
| Method-of-use protection |
Limited current value |
| Formulation differentiation |
Limited |
| Manufacturing barriers |
Potentially relevant to supply, not generally market blocking |
| Litigation leverage |
Low |
| Generic-entry exposure |
High |
A manufacturer seeking to defend the product would have more practical leverage through supply contracts, manufacturing reliability, hospital relationships, and regulatory execution than through late-stage patent litigation.
What is the financial trajectory for nelarabine?
No major manufacturer publicly reports nelarabine revenue as a standalone line item. Arranon and Atriance revenue is generally embedded within broader oncology or pharmaceutical segments. This prevents a reliable annual revenue series from public company filings.
The financial trajectory can be divided into four phases:
Launch and orphan-market formation: 2005 to roughly 2012
The product benefited from orphan status, limited treatment alternatives, and branded pricing. Demand was constrained by the small T-cell malignancy population and the use of the drug in salvage settings.
Mature branded period: roughly 2012 to generic entry
After orphan and new-molecule exclusivities expired, the product retained value through physician familiarity and inclusion in treatment protocols. Revenue growth likely depended more on treatment volume and price than on market expansion.
Generic transition
Generic entry changed the economic structure. Branded revenue became vulnerable to formulary substitution, tendering, and reduced net pricing. The reference product retained value where hospitals prioritize established supply or where generic availability is inconsistent.
Mature generic market
The long-term market is likely characterized by low-to-moderate annual unit demand, multiple suppliers, variable pricing, and periodic supply risk. The market is commercially durable because the underlying disease need persists, but it is unlikely to produce blockbuster-scale revenue.
How does nelarabine compare with newer T-cell malignancy therapies?
| Factor |
Nelarabine |
Newer targeted or cellular therapies |
| Product age |
Approved in 2005 |
Generally newer |
| Administration |
Intravenous chemotherapy |
May be oral, intravenous, or cellular |
| Population |
Relapsed or refractory T-cell disease |
Often broader or biomarker-defined |
| Patent life |
Mature |
Often substantial remaining protection |
| Price structure |
Mature branded or generic injectable |
Frequently high branded pricing |
| Manufacturing complexity |
Conventional sterile drug manufacturing |
May include complex biologic or cell-processing requirements |
| Revenue potential |
Niche |
Higher where indications and treatment volumes are broader |
| Substitution |
Salvage chemotherapy alternatives |
May replace or precede nelarabine in selected patients |
Nelarabine remains relevant where rapid cytoreduction, prior treatment history, or transplant planning supports its use. It is more exposed to clinical substitution than to direct molecule-for-molecule competition.
What generic launch scenarios exist for nelarabine?
Scenario 1: Multiple generic suppliers
Several ANDA holders compete on price, producing sustained erosion in branded share and lower average selling prices. This is the most adverse scenario for the originator.
Scenario 2: Limited generic supply
Only one or two suppliers remain active because of low market size or manufacturing economics. Prices decline less sharply, and supply continuity becomes a competitive differentiator.
Scenario 3: Shortage-driven incumbent resilience
A generic manufacturing interruption allows Arranon or another established supplier to retain hospital contracts. Revenue may remain stable temporarily even after generic approval.
Scenario 4: Clinical displacement
Use declines as physicians shift toward clinical trials, transplantation, targeted agents, or cellular therapies. This scenario reduces total market volume, not only branded share.
What patent litigation and settlement agreements affect nelarabine?
No widely reported, high-value settlement agreement or active patent litigation currently defines the nelarabine market. The absence of prominent litigation is consistent with the product’s modest revenue base and mature patent position.
For generic applicants, litigation economics are less attractive than for high-revenue chronic medicines. For the originator, a settlement would have limited strategic value unless it preserved a meaningful supply or distribution position.
What are the geographic market dynamics for nelarabine?
The United States is the most important publicly documented market because of Arranon’s FDA approval and the availability of an established generic pathway. Atriance has been marketed in other jurisdictions, including Europe, under local regulatory and reimbursement systems.[3]
Geographic performance depends on:
- National reimbursement for rare hematologic cancers.
- Hospital tender structures.
- Local generic approval timing.
- Supply-chain reliability.
- Access to transplant and specialist oncology centers.
- Differences in treatment guidelines.
The product’s intravenous administration and specialist use make hospital procurement more important than retail pharmacy distribution in most markets.
What manufacturing and intellectual-property barriers remain?
The key barrier is sterile injectable manufacturing. A prospective supplier must establish validated synthesis, formulation, aseptic filling, quality testing, and regulatory compliance. Small market size can reduce the incentive to maintain multiple commercial suppliers.
Intellectual-property barriers are less significant. Manufacturing know-how may still affect cost, yield, impurity control, and supply reliability, but it is unlikely to support a durable monopoly after foundational patents expire.
Key Takeaways
- Nelarabine is a mature orphan oncology drug used for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
- Arranon received FDA approval in 2005; its new-molecule and orphan exclusivity periods have expired.
- Generic competition, rather than biosimilar competition, is the central market risk.
- Public filings do not provide standalone nelarabine revenue, preventing a reliable product-level revenue forecast.
- The market is small, hospital-centered, and vulnerable to procurement discounts and generic substitution.
- Sterile manufacturing and supply reliability are more important current barriers than patent protection.
- No prominent current Paragraph IV litigation, late-life formulation patent, or settlement agreement defines the market.
- Revenue potential is limited by the narrow disease population, but ongoing clinical need supports a durable niche market.
FAQs
Is nelarabine still commercially available?
Yes. Nelarabine remains an FDA-approved therapy, with branded and generic injectable products depending on market and supplier availability.[1]
Is nelarabine a chemotherapy or a biologic?
Nelarabine is a conventional small-molecule antimetabolite chemotherapy. It is not a biologic and does not face biosimilar competition.
Can generic nelarabine be automatically substituted for Arranon?
Substitution depends on FDA-rated equivalence, state pharmacy law, hospital policy, and the purchasing institution. Injectable oncology products are often managed through institutional formularies and contracts.
Does nelarabine have meaningful remaining patent life?
The commercially important compound and regulatory protections are mature. Any remaining patent issues would need to be evaluated claim by claim and jurisdiction by jurisdiction, but no widely reported late-life patent barrier currently controls the market.
What is the main investment risk for nelarabine?
The main risks are generic price erosion, low treatment volume, clinical substitution, and manufacturing interruptions. The principal offset is persistent demand in a rare, serious disease with limited salvage-treatment options.
References
-
U.S. Food and Drug Administration. (2024). Arranon (nelarabine) injection: Prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2005). FDA approves Arranon for T-cell leukemia and lymphoma. FDA. https://www.fda.gov/
-
European Medicines Agency. (2007). Atriance: EPAR product information. EMA. https://www.ema.europa.eu/
